BJMO - 2023, issue Highlights in Immunotherapy Special, november 2023
J. Blokken PhD, PharmD, T. Feys MBA, MSc
Historically, surgery, with or without chemotherapy, has been the standard of care for patients with earlystage non-small cell lung cancer (NSCLC). When chemotherapy was used, a platinum-based doublet regimen has been the long-standing standard adjuvant treatment for resected patients with stage II-III disease. However, the clinical benefit that can be gained with adjuvant chemotherapy is limited, with a five-year overall survival (OS) benefit of only 5%. Moreover, despite surgery and adjuvant chemotherapy, most patients with early-stage NSCLC eventually die from disease recurrence.1 In an attempt to improve on this, several clinical trials have assessed the potential impact of integrating immunotherapy into the neoadjuvant and adjuvant treatment algorithm for patients with early-stage NSCLC.
Read moreBJMO - volume 17, issue 7, november 2023
T. Feys MBA, MSc, J. Blokken PhD, PharmD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2023;17(7):275)
Read moreBJMO - volume 17, issue 7, november 2023
J. Blokken PhD, PharmD
In this section of the BJMO, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjmo.be) and we will make sure to include it in the journal scan section of the next BJMO issue.
(BELG J MED ONCOL 2023;17(7):271–4)
Read moreBJMO - volume 17, issue 6, october 2023
J. Blokken PhD, PharmD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2023;17(6):245)
Read moreBJMO - volume 17, issue 6, october 2023
A. Enguita PhD, J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this section of the BJMO, we aim to provide a snapshot of pivotal studies published in recent issues of the most important international journals focusing on oncology. Importantly, the selection of the studies discussed here is the sole responsibility of the publisher and was not influenced by third parties. Do you miss an important study, or did you read a hidden jewel that deserves to be shared with your colleagues? Please, let us know (editor@bjmo.be) and we will make sure to include it in the journal scan section of the next BJMO issue.
(BELG J MED ONCOL 2023;17(6):239–44)
Read moreBJMO - volume 17, issue 5, september 2023
J. Blokken PhD, PharmD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2023;17(5):156)
Read moreBJMO - 2023, issue Special, july 2023
J. Blokken PhD, PharmD
Besides interesting data on novel treatment options for melanoma patients, the 19th European Association of Dermato-Oncology (EADO) congress featured several sessions on non-melanoma skin cancer. Below, we give an overview of recent advances in cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and Merkel Cell Carcinoma (MCC), as well as some promising new treatment strategies and combinations.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
